Novel Agents in Multiple Myeloma.

Novel Agents in Multiple Myeloma.
Cancer J. 2019 Jan/Feb;25(1):45-53
Authors: Szalat R, Munshi NC
Abstract
The therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last 15 years with the advent of immunomodulatory drugs and proteasome inhibitors. However, majority of MM patients relapse, and new therapies are needed. Various agents with diverse mechanisms of action and distinct targets, including cellular therapies, monoclonal antibodies, and small molecules, are currently under investigation. In this review, we report novel drugs recently approved or under advanced investigation that will likely be incorporated in the future as new standard for MM treatment, focusing on their mechanisms of action, cellular targets, and stage of development.
PMID: 30694859 [PubMed - in process]

Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Szalat R, Munshi NC Tags: Cancer J Source Type: research